Chief Scientific Officer
Principal Scientist
Chief Scientific Advisor
Sumant Ramachandra serves as an Independent Director on the Board of Lyell Immunopharma (“Lyell”), following Lyell’s acquisition of ImmPACT Bio (“ImmPACT”) in October 2024. As CEO of ImmPACT from November 2021 until its acquisition, he led capital raises, secured clinical grants, and built a team that achieved FDA clearance for three Investigational New Drug (IND) applications, established manufacturing capabilities, and advanced multiple clinical studies.
In addition, Dr. Ramachandra currently serves as an advisor to private equity funds on companies in the pharmaceuticals, biotechnology, and medical devices/software spaces.
Previously, Dr. Ramachandra served as Chief Science, Technology, and Medical Officer at Baxter International, starting in June 2017. He was also appointed President of Baxter Pharmaceuticals in 2019. Prior to Baxter, he held the role of Senior Vice President, Head of Research & Development, at Pfizer Essential Health, and served as Chief Scientific Officer at Hospira from 2008 until Pfizer acquired Hospira in 2015. Earlier in his career, Dr. Ramachandra held senior roles at Pfizer and Merck & Co., specializing in oncology, global product development, medical affairs, business development, and clinical pharmacology. He began his medical career as an intern and resident physician at Massachusetts General Hospital, Harvard Medical School.
Dr. Ramachandra earned his undergraduate degree in biochemistry, a PhD in experimental pathology (with a focus on chronic lymphocytic leukemia), and an MD from Rutgers University. He also holds an MBA from the Wharton School, University of Pennsylvania.
Scientific Advisor
Scientific Advisor
Scientific Advisor
Scientific Advisor
Flashpoint was founded on nanotechnology developed over the past 10 years in the laboratory of Chad Mirkin, Director of the International Institute for Nanotechnology at Northwestern University and 2024 winner of the prestigious Kavli Prize in Nanoscience. Flashpoint’s groundbreaking nanotechnology discovery platform enables the development of therapeutic candidates with superior product profiles. Validated in numerous in-vivo models, this technology has transformed components that are ineffective in conventional formulations into curative cancer immunotherapies. CancerVax is working with Flashpoint to deliver its novel Universal Cancer Treatment therapies using Flashpoint’s nanoparticle technology.
Cytiva, formerly Precision NanoSystems, is a part of Danaher (NYSE: DHR) and a global leader in advancing and accelerating therapeutics. With a strong presence in life sciences research and bioprocessing, Cytiva provides innovative technologies and expertise to help companies bring life-changing treatments to market. The company specializes in biomanufacturing solutions, lipid nanoparticle (LNP) development, and cutting-edge analytical tools. CancerVax is working with Cytiva to leverage its clinically proven LNPs to to create a complete CancerVax therapeutic nanoparticle.
Axis Bio is a preclinical contract research organisation with specialist capabilities in oncology, inflammation and respiratory diseases. Services range from in vitro efficacy and mechanistic studies, to in vivo target engagement, with each study tailored to the unique requirements of the client. Our clients are spread across the globe and include pharmaceutical and biotech businesses, university-based research organisations and virtual/semi-virtual development companies. We listen, guide and advise clients through every step of the preclinical efficacy testing process, to deliver clear and robust results in a timely and cost-effective manner. This approach applies whether we are simply carrying out the in-life phase of a study or providing a complete package of analysis including flow cytometry analysis, bioanalysis and blood analysis, along with a detailed interpretation of results and recommendations.
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders to enabling future pandemic response plans.
According to Precedence Research, the global biotechnology market is projected to grow from $1.3 trillion in 2023 to $3.2 trillion by 2030.
According to Fortune Business Insights, the global oncology drugs market is projected to grow from $205 billion in 2023 to $484 billion by 2030.
CancerVax, Inc., the developer of a revolutionary universal cancer treatment platform that will use the body’s immune system to fight cancer, announced today that Sumant Ramachandra, MD, PhD, MBA and founder of SR Global Health, LLC, a healthcare advisory firm, will serve as the Company’s new Chief Scientific Advisor
CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to fight cancer, today announced the successful functional validation of its innovative Smart mRNA (messenger RNA) technology in lab tests
CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to fight cancer, announced today that the Company has selected Pancreatic Ductal Adenocarcinoma (PDAC) as one of its first targets for preclinical development
CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to fight cancer, announced today that Dr. George Katibah will serve as the company’s Chief Scientific Officer
